First-Mover Licensing Advantage Gives this Company a Leg Up in Potential $2.5 Trillion Mental Health Market
Numinus Wellness Inc. (OTC:LKYSF)(TSXV:NUMI) is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy. It also appears to be the first public company in Canada to receive a license to produce and extract psilocybin from mushrooms, and to complete the first legal harvest of psilocybin-producing mushrooms in Canada.
Psychedelics could soon revolutionize the $2.5 trillion mental health market.
All with psychedelic drugs like psilocybin.
It’s part of the reason that Eight Capital estimates the total market for mental health treatment could be valued at up to $100 billion.(11)
Are There Higher Highs Ahead for Psychedelics, like Psilocybin & MDMA?
For one, the US FDA is backing research into psilocybin, through a series of approvals granting “breakthrough therapy” status to psilocybin research efforts in the US.(4)
Numinus Bioscience harvests the first legal flush of Psilocybe mushrooms at its 7000 square foot research and development lab (Numinus Wellness Inc.)
Two, clinical studies from the likes of Johns Hopkins and New York University are already showing positive results, furthering the FDA’s breakthrough therapy status designations. Other studies show similar trends:
- A study from JAMA Psychiatry just found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.(5)
- Johns Hopkins Medicine launched the Center for Psychedelic and Consciousness Research to study compounds like LSD and psilocybin to treat a range of mental health problems, including anorexia, addiction and depression.(6)
- A study in the journal, Nature— Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms – showed that 47% of treatment-resistant patients with depression showed positive responses five weeks after psilocybin treatments.(7)
Three: states across the US have initiated promising policy reform that is steadily trending upward. In November alone, Oregon decriminalized all drugs in one measure and legalized psychedelics in another, while Washington DC decriminalized use of natural psychedelics. Meanwhile, the cities of Denver, Oakland and Santa Cruz have also taken similar steps, decriminalizing the possession of personal-use amounts of drugs.(8)
Four, investor attention is rapidly ramping up across North America and Europe
- Compass Pathways became the first to break into U.S. markets, and has become one of the most valuable psychedelic stocks on the market with a market cap of $1.21 billion.(10)
- ATAI recently raised $125M, with lead orders from COMPASS backers Peter Thiel and Christian Angermayer
- MindMed was first to enter the market and now has a market cap of over $600 million backed by former Canopy CEO, Bruce Linton, and Kevin O’Leary of Shark Tank fame.(9)
This combination of robust clinical research and growing investor attention makes a mainstream industry surge only a matter of time, including attention from major pharmaceutical companies—and Numinus is perfectly positioned with its ecosystem lying at the intersection of scientific research, therapy development and therapy delivery.
Appears To Be The First Canadian Psychedelics Company to Legally Harvest Magic Mushrooms
Numinus Wellness Inc. (OTC:LKYSF)(TSXV:NUMI) is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy.
It seems to be the first public company in Canada to receive a license to produce and extract psilocybin from mushrooms, issued by Health Canada. With that license, Numinus has now completed the first legal harvest of psilocybe mushrooms in Canada by a public company. The license also allows Numinus to test, import, store, and distribute psilocybin and psilocin.
According to the company:
Numinus also possesses a dealer’s license from Health Canada to import, expert, possess, test, and distribute MDMA, psilocybin, psilocin, DMT, and mescaline.
However, That’s Just a Fraction of the Numinus Wellness Growth Story
Other recent developments include:
Numinus Health — Numinus’s existing wellness clinic where psychedelic-assisted psychotherapy will be delivered by industry leading practitioners, once regulated. The site is currently the beta-testing site for psychedelic protocols, while also delivering non-psychedelic services for revenue generation. Upgrades have commenced to retrofit the clinic to specifications set by psychedelic therapy industry leader, the Multidisciplinary Association of Psychedelics Studies (MAPS), thereby setting a blueprint for Numinus to develop a network of clinics nationally and internationally.
Numinus R&D — Numinus’s medical unit for therapeutic protocol development, in partnership with regulators and leading research institutions. Research is underway to support the company’s stated strategic plan to undertake psilocybin and MDMA clinical research. Numinus recently announced its first clinical trial, for psilocybin-assisted psychotherapy to treat substance use disorders.
Numinus Bioscience — Numinus’s Health Canada-licensed laboratory for psychedelic substance research. It currently holds the company’s first-in-country license by a public company to develop proprietary cultivation and extraction methods for psilocybin from mushrooms, through which it has completed the first mushroom harvest. Other licensing rights include a dealer’s licence to import, export, possess, test, and distribute MDMA, psilocybin, psilocin, DMT, and mescaline; and a cannabis testing licence to provide 3rd-party analytics & testing services for revenue generation. The significant license application processes which Numinus has successfully completed present a high barrier to entry for other market entrants.
After pulling back from an approximately $1.01 high close to less than about 20 cents, shares of NUMI pushed back to 80 cents in recent weeks. At the moment, it would appear that investors are just beginning to recognize the value of the company. No doubt this has also been helped by a recent $25M bought deal for the company’s peer, MindMed, which trades at a much higher valuation.
Plus, its short-, medium-, and long-term indicators are all positive, including its 20-day MA, 20-50 day MACD oscillator, 20-100 day MACD oscillator, 20-200 day MACD oscillator, 50-day MA, 50-100 day MACD oscillator, 50-150 day MACD oscillator, 50-200 day MACD oscillator, 100-day MA, 150-day MA, 200-day MA, and its 100-200 day MACD oscillator.
Successful companies tend to possess common traits, and one of those traits is a strong management team. Numinus Wellness certainly has that ground covered. The company appears to have done a spectacular job of bringing together a leadership team that exists at the intersection of science-based research, policy making, finance, and notable names in the psychedelic space.
Payton Nyquvest, Chairman and CEO
Former Director, VP and Head of Sales at Mackie Research Capital, one of Canada’s largest independent brokerage firms, with a focus on public health and human advancement. Fifteen years’ experience in investment banking, has raised over $100 million for 100+ public and private companies. Former investment advisor with Jordan Capital Markets, Canaccord Financial.
Stacey Wallin, Chief Strategy Officer
Former founder and CEO of LifeBooster, a tech startup now helping Fortune 100 clients detect and proactively respond to workplace injury risks. She most recently was the Director of Venture Programs at the BC Tech Association, leading the team developing accelerators for scale companies in BC with a mandate of solving the largest ecosystem and policy-related challenges facing growth and scale stage technology companies. Also founded and runs the Canadian Accelerator Incubator Network.
Dr. Evan Wood, MD, PhD, Chief Medical Officer
Recognized researcher with 20+ years of experience in addiction research, most recently as Executive Director of British Columbia Centre on Substance Use (BCCSU). Professor of Medicine at the University of British Columbia. Work on psychedelic-assisted psychotherapy includes involvement with the Multidisciplinary Association for Psychedelics Studies (MAPS) trial of MDMA-assisted psychotherapy and examining the potential of psilocybin assisted psychotherapy for a range of mental health disorders. Dr. Wood was instrumental in the creation of Canada’s supervised injection sites and won in the Supreme Court of Canada to make the program a reality. He was also heavily involved in the creation of international best-practice standards for the HIV/AIDS epidemic and the research that took cannabis into legal status in Canada.
John Fong, Chief Financial Officer
Experienced financial operator growing technology companies for the past five years, most recently as Managing Director of Invoke Digital. Prior to that, spent 15 years building international financial operations with companies listed on the TSX, NYSE, London AIM, and Lima Stock Exchange, the highlight of which was being on the founding team of Rio Alto Mining, a gold company that in three years went from exploration stage to generating net income of $100 million and operating cash flow of $98 million in its first year of commercial production.
Michael Tan, Chief Operating Officer
Former/first Executive Director, BCLDB Cannabis Division. Successfully launched recreational cannabis operations in BC. Twenty years’ operations management, strategic planning, and execution with national and multinational corporations including Hudson’s Bay, Saks Fifth Avenue, and UPS. Seasoned, high-impact operations, product development, and marketing executive with a track record of driving performance excellence and profitable revenue growth.
Dana Harvey, Chief Communications Officer
Award-winning professional communicator and leader with 25+ years global experience in-house, agency-side, and independent. Honed expertise in strategizing and executing high impact, complex communication requirements for disruptive concepts, emerging industries, and groundbreaking technologies. External communications efforts have resulted in total raises of $60M+, and internal communications leadership has been recognized with multiple awards including the Canadian HR Best Employer Branding Award (2019).
Dr. Devon Christie, MD, CCFP, IFMCP, RTC, Medical Director and Member of Clinical Advisory Council
Family physician with a focused practice in Multidisciplinary Pain Management and Registered Therapeutic Counselor, emphasizing Relational Somatic Therapy for trauma resolution. Teacher in the Certificate in Psychedelic-Assisted Therapies and Research post-graduate program at the California Institute of Integral Studies (CIIS). Trained to deliver MDMA-assisted psychotherapy for PTSD (MAPS USA) and ktamine-assisted psychotherapy. Certified in Functional Medicine, Mindfulness-Based Street Reduction, Interpersonal Mindfulness, and Kundalini Yoga. Recognized speaker and expert on the potential of incorporating psychedelic-assisted therapies in an integrated healthcare model.
Sharan Sidhu, Science Officer and General Manager
Extensive experience as a key strategist for research roadmaps, core initiatives and the development of research requirements and management of research projects and the development of IP. Worked as a hub between academia, industry, and governing directorates to ensure research and development objectives meet regulatory compliance at all phases of pipelines from inception to commercialization. Regulatory expert and policy advisor for restrictive high growth industries. Managed several compliance projects as well as developed requirements for LIMS, GLP, GACP, GMP as well as methods development, vendor qualification, ISO standards and training. Developed several good practices policies and quality management systems and implemented mass change control and overall, all reduction in deviations.
Source A: https://www.newswire.ca/news-releases/numinus-first-canadian-public-company-to-complete-legal-harvest-of-psilocybe-mushrooms-849901430.html
Source 1: https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows
Source 2: https://www.nimh.nih.gov/about/directors/thomas-insel/blog/2015/mental-health-awareness-month-by-the-numbers.shtml
Source 3: https://ca.finance.yahoo.com/news/wall-street-eyes-mental-health-as-the-next-great-growth-story-132619645.html
Source 4: https://www.livescience.com/psilocybin-depression-breakthrough-therapy.html
Source 5: https://www.npr.org/sections/health-shots/2020/11/04/931377532/rigorous-study-backs-a-psychedelic-treatment-for-major-depression
Source 6: https://www.nytimes.com/2019/09/04/science/psychedelic-drugs-hopkins-depression.html
Source 7: https://www.nature.com/articles/s41598-017-13282-7
Source 8: https://www.oregonlive.com/politics/2020/11/oregon-becomes-first-state-to-legalize-psychedelic-mushrooms.html
Source 9: https://www.thecannabisinvestor.ca/mindmed-becomes-first-psychedelics-firm-to-go-public-following-historic-ipo/
Source 10: https://observer.com/2020/10/why-magic-mushrooms-are-the-next-big-booming-and-legal-drug-market/
Source 11: https://www.prnewswire.com/news-releases/numinus-commences-psilocybe-mushroom-cultivation-at-its-health-canada-licensed-laboratory-301137266.html
Source 12: https://www.prnewswire.com/news-releases/numinus-commences-psilocybe-mushroom-cultivation-at-its-health-canada-licensed-laboratory-301137266.html
This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors
We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 11/30/20 and ending on 12/25/20 to publicly disseminate information about (NUMI) via digital communications. We have been paid fifty thousand USD via bank wire transfer. We own zero shares of (NUMI).
Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 12/14/20 and ending on 12/28/20 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional one hundred thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid one hundred fifty thousand USD via bank wire transfer. We own zero shares of (NUMI).
Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 12/21/20 and ending on 12/28/20 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional fifty thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid two hundred thousand USD via bank wire transfer. We own zero shares of (NUMI).
Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 12/26/20 and ending on 01/26/21 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional seventy five thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid two hundred seventy five thousand USD via bank wire transfer. We own zero shares of (NUMI).
Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 1/20/21 and ending on 02/18/21 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional one hundred thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid three hundred seventy five thousand USD via bank wire transfer. We own zero shares of (NUMI).
Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 02/19/21 and ending on 02/26/21 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional forty thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid four hundred fifteen thousand USD via bank wire transfer. We own zero shares of (NUMI).
Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 03/1/21 and ending on 03/12/21 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional forty thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid four hundred fifty-five thousand USD via bank wire transfer. We own zero shares of (NUMI).